Sandeep Das

About

As a highly motivated and dedicated postdoctoral fellow, I am excited to embark on the next phase of my scientific journey, specializing in metabolic disorders. With a strong background in cellular and molecular biology, I have developed a profound fascination for understanding the intricate mechanisms underlying metabolic dysregulations, particularly in disorders such as obesity, insulin resistance, diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), Metabolic dysfunction-associated steatohepatitis (MASH), and atherosclerotic cardiovascular diseases. Through my research experiences and accomplishments thus far, I am driven by my desire to unravel the complexities of metabolic pathways and explore novel therapeutic targets for addressing the growing burden of cardiometabolic diseases in today's society.

Employment

• The Assam Royal Global University Assistant Professor
  2026 - Present
• LSU Health Shreveport Postdoc Fellow
  2021 - 2026

Education

• Tripura University Ph.D.

Projects & Funding

Projects & funding information is unavailable.

Publications (23)

• Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1
  Journal of Medicinal Chemistry 2026 DOI: 10.1021/acs.jmedchem.5c02055
  +Save
• Neutrophil CD14 is a driver and a therapeutic target for deep vein thrombosis
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2025017224
  +Save
• Protective effects of Bambusa vulgaris leaves extract on high-fat diet-induced MASLD: insights from in silico and in vivo study
  3 Biotech 2026 DOI: 10.1007/s13205-026-04735-w
  +Save
• Sex-based multiomics analysis uncovers metabolic and molecular mediators linking MASH and atherosclerosis
  JHEP Reports 2026 DOI: 10.1016/j.jhepr.2025.101703
  +Save
• Dietary calcium ameliorates cardiac dysfunction by regulating adiponectin-AMPK–mediated pathway in obese rats
  Comparative Clinical Pathology 2025 DOI: 10.1007/s00580-025-03692-9
  +Save
• Neutrophil Integrin α9 Impairs Efferocytosis and Worsens Long-Term Recovery after Subarachnoid Hemorrhage
  Arteriosclerosis Thrombosis and Vascular Biology 2025 DOI: 10.1161/ATVBAHA.125.323072
  +Save
• Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease
  Experimental Neurology 2025 DOI: 10.1016/j.expneurol.2025.115181
  +Save
• Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis
  Nature Metabolism 2024 DOI: 10.1038/s42255-024-01134-4
  +Save
• Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis
  Journal of Thrombosis and Haemostasis 2024 DOI: 10.1016/j.jtha.2024.08.023
  +Save
• The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
  Frontiers in Cardiovascular Medicine 2023 DOI: 10.3389/fcvm.2023.1116861
  +Save